{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Gaggl M"],"pubmed_abstract":["<h4>Background</h4>The SARS-CoV-2 pandemic increased mortality and morbidity among immunocompromised populations. Vaccination is the most important preventive measure, however, its effectiveness among patients depending on maintenance immunoglobulin G (IgG) apheresis to control autoimmune disease activity is unknown. We aimed to examine the humoral immune response after mRNA-1273 Moderna<sup>®</sup> vaccination in immunoapheresis patients.<h4>Methods</h4>We prospectively monitored SARS-CoV-2 IgG spike (S) protein antibody levels before and after each IgG (<i>exposure</i>) or lipid (LDL) apheresis (<i>controls</i>) over 12 weeks and once after 24 weeks. Primary outcome was the difference of change of SARS-CoV-2 IgG S antibody levels from vaccination until week 12, secondary outcome was the "],"journal":["Frontiers in immunology"],"pagination":["969193"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9549982"],"repository":["biostudies-literature"],"pubmed_title":["SARS-CoV-2 IgG spike protein antibody response in mRNA-1273 Moderna<sup>®</sup> vaccinated patients on maintenance immunoapheresis - a cohort study."],"pmcid":["PMC9549982"],"pubmed_authors":["Strassl R","Gaggl M","Aigner C","Bond G","Schmidt A","Vychytil A","Wagner L","Aschauer C","Sunder-Plassmann G"],"additional_accession":[]},"is_claimable":false,"name":"SARS-CoV-2 IgG spike protein antibody response in mRNA-1273 Moderna<sup>®</sup> vaccinated patients on maintenance immunoapheresis - a cohort study.","description":"<h4>Background</h4>The SARS-CoV-2 pandemic increased mortality and morbidity among immunocompromised populations. Vaccination is the most important preventive measure, however, its effectiveness among patients depending on maintenance immunoglobulin G (IgG) apheresis to control autoimmune disease activity is unknown. We aimed to examine the humoral immune response after mRNA-1273 Moderna<sup>®</sup> vaccination in immunoapheresis patients.<h4>Methods</h4>We prospectively monitored SARS-CoV-2 IgG spike (S) protein antibody levels before and after each IgG (<i>exposure</i>) or lipid (LDL) apheresis (<i>controls</i>) over 12 weeks and once after 24 weeks. Primary outcome was the difference of change of SARS-CoV-2 IgG S antibody levels from vaccination until week 12, secondary outcome was the ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-04T21:41:08.115Z","creation":"2024-10-18T11:16:27.861Z"},"accession":"S-EPMC9549982","cross_references":{"pubmed":["36225921"],"doi":["10.3389/fimmu.2022.969193"]}}